ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ALLR Allarity Therapeutics Inc

1.36
-0.01 (-0.73%)
Last Updated: 00:14:19
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Allarity Therapeutics Inc ALLR NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.01 -0.73% 1.36 00:14:19
Open Price Low Price High Price Close Price Previous Close
1.37 1.30 1.3821 1.37
more quote information »

Recent News

Date Time Source Heading
17/4/202423:10GLOBEAllarity Therapeutics Receives NASDAQ-Approved Extension to..
05/4/202400:15GLOBEAllarity Therapeutics Announces 1-for-20 Reverse Stock Split
27/3/202423:30GLOBEAllarity Therapeutics Makes Strategic Pivot to Focus Solely..
25/3/202422:30GLOBEAllarity Therapeutics Receives Extension from Nasdaq..
09/3/202400:38EDGAR2Form 8-K - Current report
08/3/202423:15EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
08/3/202423:15GLOBEAllarity Therapeutics Reports Full Year 2023 Financial..
08/3/202413:45EDGAR2Form DEF 14A - Other definitive proxy statements
05/3/202408:05EDGAR2Form 8-K - Current report
02/3/202401:21EDGAR2Form 8-K - Current report
28/2/202422:00GLOBEAllarity Therapeutics to Present at Biomarkers 2024
24/2/202408:09EDGAR2Form PRER14A - Preliminary Proxy Soliciting materials
15/2/202401:03EDGAR2Form 8-K - Current report
03/2/202409:03EDGAR2Form D - Notice of Exempt Offering of Securities
02/2/202408:40EDGAR2Form 8-K - Current report
27/1/202409:07EDGAR2Form PRE 14A - Other preliminary proxy statements
26/1/202409:24EDGAR2Form 8-K - Current report
20/1/202409:29EDGAR2Form 8-K - Current report
16/12/202309:00EDGAR2Form S-1/A - General form for registration of securities..
12/12/202322:00GLOBEAllarity Therapeutics Announces Thomas Jensen as Interim CEO..
11/12/202322:30EDGAR2Form 8-K - Current report
07/12/202309:00EDGAR2Form 8-K - Current report
07/12/202300:30EDGAR2Form S-1/A - General form for registration of securities..
05/12/202323:30EDGAR2Form 8-K - Current report
05/12/202323:30GLOBEAllarity’s Early Phase 2 Stenoparib Data Indicates Clinical..
18/11/202309:01EDGAR2Form 8-K - Current report
14/11/202300:35EDGAR2Form 8-K - Current report
03/11/202308:00EDGAR2Form S-3 - Registration statement under Securities Act of..
01/11/202300:30EDGAR2Form S-1 - General form for registration of securities under..
31/10/202308:00EDGAR2Form 8-K - Current report
24/10/202308:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
18/10/202308:00EDGAR2Form S-3/A - Registration statement under Securities Act of..
11/10/202308:00EDGAR2Form S-3 - Registration statement under Securities Act of..
02/10/202322:00GLOBEAllarity Therapeutics to Present at Biomarkers Europe 2023
28/9/202306:30EDGAR2Form 8-K - Current report
15/9/202322:45EDGAR2Form 8-K - Current report
31/8/202306:05GLOBEPLOS ONE Publishes Data on Allarity Therapeutics’ DRP®..
15/8/202305:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202322:15EDGAR2Form 8-K - Current report
31/7/202320:00GLOBEAllarity Therapeutics and FivepHusion Announce Collaboration..
28/7/202306:01EDGAR2Form 8-K - Current report
24/7/202320:00GLOBEAllarity Therapeutics Strengthens Board of Directors with..
18/7/202307:10EDGAR2Form 8-K - Current report
12/7/202306:05EDGAR2Form 8-K - Current report
08/7/202306:30EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
06/7/202320:05EDGAR2Form 8-K - Current report
06/7/202320:00GLOBEAllarity Therapeutics, Inc. Announces Pricing of $11 Million..
06/7/202306:31EDGAR2Form 8-K - Current report
05/7/202323:45GLOBEInitial Data from Allarity’s Phase 2 Trial of IXEMPRA®..
01/7/202307:23EDGAR2Form S-1/A - General form for registration of securities..

Your Recent History

Delayed Upgrade Clock